Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk management program couldn't save psoriasis drug. Decision is final, firm says.

You may also be interested in...

Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response

Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006

Roche Wins Genentech After Months-Long Battle

The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.

Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials

President Obama praises Hamburg's "reputation of integrity" and record of public health acheivements in making nominations March 14.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts